OS Therapies Inc
OSTXdata completeness 75%3 fiscal years on fileData notes: no data for concept 'revenue'; no data for concept 'interestExpense'; no data for concept 'incomeTaxExpense'; no data for concept 'pretaxIncome'
i. The business — what you’d actually own
| Figure | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | −$7.79M1 | −$8.88M2 | −$28.8M2 |
| Operating cash flow | −$3.01M3 | −$7.28M4 | −$14.2M4 |
| Capital expenditure | — | — | $466,4235 |
| Free cash flow (derived) | — | — | −$14.7M4 |
| Total debt | — | — | — |
| Cash & equivalents | $38,9826 | $5.53M6 | $269,8306 |
| Diluted shares | 5.4M | 7.0M | 29.3M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$2.08
your share of equity
Profit it earned you last year
−$9.83
Free cash flow it threw off
−$5.03
Debt you’d be carrying
—
10 shares is a claim on −$2.08 of net worth that earned you −$9.83 and generated −$5.03 of cash last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 3y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+439% shares · 3y
Share count is up 439% over 3 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2023-12-31 · accession 0001213900-25-026238 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-036629 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-026238 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-036629 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2025-12-31 · accession 0001213900-26-036629 (PaymentsToAcquireProductiveAssets)
- 10-K · period ending 2023-12-31 · accession 0001213900-26-036629 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)